miR-216b Targets FGFR1 and Confers Sensitivity to Radiotherapy in Pancreatic Ductal Adenocarcinoma Patients Without EGFR or KRAS Mutation.

EGELİ Ü., Tezcan G., ÇEÇENER G., TUNCA B., Sevinc E. D., KAYA E., ...More

Pancreas, vol.45, no.9, pp.1294-302, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 45 Issue: 9
  • Publication Date: 2016
  • Doi Number: 10.1097/mpa.0000000000000640
  • Journal Name: Pancreas
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1294-302
  • Keywords: pancreatic ductal adenocarcinoma, EGFR, KRAS, miR-216b, FGFR1, radiotherapy resistance, COLORECTAL-CANCER, GEMCITABINE, PROGRESSION, METASTASIS, INHIBITION, MICRORNAS, PROGNOSIS, CARCINOMA, INVASION, IMPACT
  • Bursa Uludag University Affiliated: Yes

Abstract

Objectives: The success of gemcitabine plus radiotherapy is dependent on the mutation status of pancreatic ductal adenocarcinoma (PDAC) tumors in the EGFR and KRAS genes; however, radiotherapy resistance may also be modulated epigenetically by microRNA (miRNA) regulation. In this study, we examined the potential effect of miRNAs on the resistance to radiotherapy in cases without EGFR or KRAS mutation.